Abstract
Background Real-time reverse transcription polymerase chain reaction (RT-qPCR) is the current recommended laboratory method to diagnose SARS-CoV-2 acute infection, several factors such as requirement of special equipment, time consuming, high cost and skilled staff limit the use of these molecular techniques. A more rapid and high-throughput method is in growing demand.
Methods Evaluate the performances of the Panbio™ COVID-19 AG Rapid Test Device (Nasopharyngeal), a rapid immunochromatographic test for the detection of SARS-CoV-2 antigen, in comparison to RT-qPCR.
Results The RDT evaluated in this study showed a high sensitivity and specificity in samples mainly obtained during the first week of symptoms and with high viral loads.
Conclusions This assay seems to be an effective strategy for controlling the COVID-19 pandemic for the rapid identification and isolation of SARS-CoV-2 infected patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the ethical requirements established by the Declaration of Helsinki. The Ethics Committee of Hospital Universitario Principe de Asturias (Madrid) approved the study. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author, M.Linares, upon reasonable request.
Abbreviations
- COVID-19
- Coronavirus disease 2019
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- NP
- Nucleocapsid protein
- LFA
- Lateral flow assay
- FDA
- Food and Drug Administration
- RT-qPCR
- Real-time reverse transcription polymerase chain reaction
- RDT
- Rapid diagnostic test.
